Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II,Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Safety,Efficacy and Immunogenicity of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines

NCT05743634 is registered in ClinicalTrials.gov with Chongqing Claruvis Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05743634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05743634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II,Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study to Evaluate the Safety,Efficacy and Immunogenicity of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
Lead sponsor
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
March 22, 2022
Completion date
February 13, 2023
Enrollment
140 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe glabellar lines